43 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in May 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2037
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2037 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Mar 2041 · High confidence
Spirocyclic Degronimers for Target Protein Degradation
US 10,660,968
Cited by 68 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037.
Heterocyclic Degronimers for Target Protein Degradation
US 10,646,575
Cited by 66 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037.
Compounds for Targeted Degradation of BRD9
US 11,691,972
Cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Isoindolinone and Indazole Compounds for the Degradation of Egfr (US 11,673,902) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for Compounds for Targeted Degradation of BRD9 (US 11,691,972) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Cereblon Binders for the Degradation of Ikaros (US 11,753,397) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 2 fees due Apr 17 to 30, 2027 · next Apr 17
- 1 fee due Nov 12, 2027The maintenance fee for Heterocyclic Degronimers for Target Protein Degradation (US 10,646,575) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 18, 2026
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds for Targeted Degradation of BRD9 | 3 in force | to Mar 2041 |
| Isoindolinone and Indazole Compounds for the Degradation of Egfr | 3 in force | to Dec 2040 |
| C3-CARBON Linked Glutarimide Degronimers for Target Protein Degradation | 3 in force | to Oct 2038 |
| Dihydrobenzimidazolones for Medical Treatment | 3 in force | to Sep 2038 |
| N/O-Linked Degrons and Degronimers for Protein Degradation | 3 in force | to Jul 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,646,575 | Heterocyclic Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 10,660,968 | Spirocyclic Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 10,849,982 | C3-CARBON Linked Glutarimide Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 10,905,768 | Heterocyclic Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 11,185,592 | Spirocyclic Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 12,048,748 | Spirocyclic Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 12,605,450 | C3-CARBON Linked Glutarimide Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 12,048,747 | Substituted Piperidine Degronimers for Target Protein Degradation In force · High confidence | In force | High confidence | |
| US 12,076,405 | Heterocyclic Degronimers for Target Protein Degradation In force · Medium confidence | In force | Medium confidence | |
| US 12,180,225 | N/O-Linked Degrons and Degronimers for Protein Degradation In force · High confidence | In force | High confidence |
Also on record, not counted in the 43: 24 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.